# Sinogene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sinogene

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.sinogene.com.cn
- Latest round: Series B (Aug 18, 2021)
- Investors on record: 5

## About

Established in 2012 and based in Beijing, China, Sinogene operates as a biotechnology company that focuses on pet cloning and gene editing. In 2021, the company has completed five rounds of financing.

The company provides services of cat cloning, dog cloning, horse cloning, and cell preservation. The gene preservation (GP) consists in storing the pet genetic material so that it can be used even after decades. The Genetic preservation is accomplished by freezing the initial cell, tissue or germ plasma in the liquid nitrogen with low temperature.

## Funding rounds

- Series B, Aug 18, 2021 — Tianjin Ringpu Bio-technology, YuanBio Venture, Beijing New Aerotropolis Fund Management Co.,Ltd
- Series B, Jun 23, 2020 — Shuncheng Equity Investment Fund
- Series A, Sep 1, 2018 — CCB International Asset Management

## Investors

- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series A
- Shuncheng Equity Investment Fund (https://capitalatlas.ai/funds/shuncheng-equity-investment-fund) — Series B
- Tianjin Ringpu Bio-technology — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Beijing New Aerotropolis Fund Management Co.,Ltd — Series B